Ryan Gentzler, MD, MS, FASCO (@ryangentzler) ranks #32 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 5 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DeLLphi-305. CMS Open Payments lists $9,946 in 2025 general payments.
At a Glance
- 2 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #32 · 5 physicians engaged
- CMS Open Payments lists $9,946 in 2025 general payments.
This Month
What Ryan Gentzler, MD, MS, FASCO has posted in the last 30 days. Updated November 10, 2026.
Expert discussion of DeLLphi-305 by @StephenVLiu. Bringing tarlatamab to maintenance is major advance as second line tarlatamab is often “a promise we cannot keep.” Many patients never receive 2nd line. #ESMO26 https://t.co/T6IRxIS8ev
Excited to see the highly anticipated DeLLphi-305 at #ESMO26. First line maintenance tarlatamab + durvalumab improves PFS and OS. Updated label for outpt monitoring hopefully make this more accessible for all #SCLC patients. The next frontier: Limited Stage consolidation https://t.co/GaX09tjke2
Who Amplifies Ryan Gentzler, MD, MS, FASCO
Physicians who reposted Ryan Gentzler, MD, MS, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #32 | — | 5 | 8 | Full ranking |
Trials Ryan Gentzler, MD, MS, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DeLLphi-305 | 2 | #36 of 86 | Oct 24, 2026 |
Ryan Gentzler, MD, MS, FASCO on DeLLphi-305
Expert discussion of DeLLphi-305 by @StephenVLiu. Bringing tarlatamab to maintenance is major advance as second line tarlatamab is often “a promise we cannot keep.” Many patients never receive 2nd line. #ESMO26 https://t.co/T6IRxIS8ev
Excited to see the highly anticipated DeLLphi-305 at #ESMO26. First line maintenance tarlatamab + durvalumab improves PFS and OS. Updated label for outpt monitoring hopefully make this more accessible for all #SCLC patients. The next frontier: Limited Stage consolidation https://t.co/GaX09tjke2
Ryan Gentzler, MD, MS, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Iza-Bren continues to impress in 2nd line phase 3 for EGFR-mut lung cancer. Global study enrolling in the US with recent amendment to allow chemo+amivantamab control arm. NCT07100080 #ESMO26 https://t.co/NOiDW7FVyr https://t.co/TlgXLXPIoP
Rebecca Heist @MGHThoracicOnc breaks down the latest data on MET + EGFR TKIs. Targeting MET at time of resistance, but now also compelling data first line for those with de novo MET. Questions remain around how to test for MET positivity (IHC, amplification, cutoffs) #ESMO26 https://t.co/h8NzeGc3lq
Another memorable quote from this talk: “these data deliver real hope where hope has been in short supply”
Industry Payments
CMS Open Payments · 2025 general payments
$9,946 across 10 payments